ERBB2 and breast cancer: This approach is particularly relevant for TNBC and HER2+ BC, the aggressive forms of BC, because of their high expression of programmed cell death ligand 1 (PD-L1) and the presence of tumor-infiltrating lymphocytes (TILs) [106].